基于生境影像组学从脑转移瘤预测外显子19和外显子21的EGFR突变
研究纳入中心1的170例、中心2的62例和中心3的61例非小细胞肺癌脑转移患者,从增强T1加权和T2加权MRI的肿瘤活跃区和瘤周水肿区提取影像组学特征,构建预测EGFR突变、外显子19和外显子21的模型。瘤周水肿区模型优于肿瘤活跃区模型,联合模型在训练集和内部及外部验证集中AUC最高分别达0.955、0.882和0.830,结论认为该模型可准确预测EGFR突变亚型,可能有助于指导个体化治疗。
要点
- 瘤周水肿区影像组学特征对EGFR突变、外显子19和外显子21的预测效能优于肿瘤活跃区。
- 联合肿瘤活跃区和瘤周水肿区的模型在训练集和验证集中均获得最高AUC。
- 模型基于增强T1加权和T2加权MRI,可用于术前预测EGFR突变亚型。
核心结论
- 基于生境的影像组学模型可准确预测EGFR突变亚型,可能有助于指导非小细胞肺癌脑转移患者的个体化治疗。
研究设计与样本
- 多中心研究,中心1纳入170例、中心2纳入62例、中心3纳入61例患者,均接受增强T1加权和T2加权MRI扫描,以生境影像组学方法构建预测模型并进行内部和外部验证。
关键影像表现/征象
- 从每层MRI的肿瘤活跃区和瘤周水肿区提取影像组学特征。
- 分别鉴定出10个、4个和6个与EGFR突变状态、外显子19和外显子21强相关的预测特征。
- 基于瘤周水肿区的影像组学特征在预测EGFR突变、外显子19和外显子21方面均优于基于肿瘤活跃区的特征。
- 联合模型在训练集、内部验证集、外部验证集1和外部验证集2中均表现出最高效能。
诊断标准与关键数值
- 联合模型预测EGFR突变的AUC在训练集为0.955、内部验证集为0.879、外部验证集1为0.830、外部验证集2为0.812。
- 联合模型预测外显子19的AUC在训练集为0.946、内部验证集为0.819、外部验证集1为0.825、外部验证集2为0.818。
- 联合模型预测外显子21的AUC在训练集为0.928、内部验证集为0.882、外部验证集1为0.822、外部验证集2为0.800。
临床应用与阅片要点
- 作者认为该模型可能有助于指导非小细胞肺癌脑转移患者的个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To explore and externally validate habitat-based radiomics for preoperative prediction of epidermal growth factor receptor (EGFR) mutations in exon 19 and 21 from MRI imaging of non-small cell lung cancer (NSCLC)-originated brain metastasis (BM).
METHODS: A total of 170, 62 and 61 patients from center 1, center 2 and center 3, respectively were included. All patients underwent contrast-enhanced T1-weighted (T1CE) and T2-weighted (T2W) MRI scans. Radiomics features were extracted from the tumor active (TA) and peritumoral edema (PE) regions in each MRI slice. The most important features were selected by the least absolute shrinkage and selection operator regression to develop radiomics signatures based on TA (RS-TA), PE (RS-PE) and their combination (RS-Com). Receiver operating characteristic (ROC) curve analysis was performed to access performance of radiomics models for both internal and external validation cohorts.
RESULTS: 10, four and six most predictive features were identified to be strongly associated with the EGFR mutation status, exon 19 and exon 21, respectively. The RSs derived from the PE region outperformed those from the TA region for predicting the EGFR mutation, exon 19 and exon 21. The RS-Coms generated the highest performance in the primary training (AUCs, RS-EGFR-Com vs. RS-exon 19-Com vs. RS-exon 21-Com, 0.955 vs. 0.946 vs. 0.928), internal validation (AUCs, RS-EGFR-Com vs. RS-exon 19-Com vs. RS-exon 21-Com, 0.879 vs. 0.819 vs. 0.882), external validation 1 (AUCs, RS-EGFR-Com vs. RS-exon 19-Com vs. RS-exon 21-Com, 0.830 vs. 0.825 vs. 0.822), and external validation 2 (AUCs, RS-EGFR-Com vs. RS-exon 19-Com vs. RS-exon 21-Com, 0.812 vs. 0.818 vs. 0.800) cohort.
CONCLUSION: The developed habitat-based radiomics model can be used to accurately predict the EGFR mutation subtypes, which may potentially guide personalized treatments for NSCLC patients with BM.
引用
- Yang C, Fan Y, Zhao D, et al. Habitat-Based Radiomics for Predicting EGFR Mutations in Exon 19 and 21 From Brain Metastasis. Acad Radiol. 2024. PMID: 38599906. doi:10.1016/j.acra.2024.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。